CLINICAL AND MOLECULAR HEPATOLOGY

Pre-infection UDCA use was not associated with reduced risk for most long COVID outcomes in patients with SLD.

Read more:
doi.org/10.3350/cmh.20…

#LongCOVID #UDCA #SLD #LiverDisease #CMH

Elevated liver MRI-derived cT1 may reflect systemic patho physiological processes associated with extrahepatic cancer risk.

Read more:
doi.org/10.3350/cmh.20…

#cT1 #MRI #LiverDisease #CancerRisk #Biomarker #CMH

DYNAMO model, incorporating LSM status and clinical covariates, enables personalized surveillance in MASLD.

Read more:
doi.org/10.3350/cmh.20…

#MASLD #Vibration_controlled_transient_elastography #LiverFibrosis #LiverStiffness #RiskPrediction #CMH

LATS2 inactivation drives immunosuppressive microenvironment and anti-PD-1 resistance, which can be reversed by YAP inhibition.

Read more:
doi.org/10.3350/cmh.20…

#ICC #LATS2 #PD_L1 #Immunotherapy #CMH

Rifaximin use was not associated with the development of drug-resistant organisms in this cohort of inpatients with cirrhosis.

Read more:
doi.org/10.3350/cmh.20…

#Rifaximin #Cirrhosis #DrugResistantOrganisms #CMH